Skip to main content

Table 2 Median/Mean Values of Spirometry, Blood Eosinophil Count, TSIgE and Serum Cytokines, Prevaccination and Postvaccination on Both Groups on First and Second Phases

From: Clinical Efficacy and Laboratory Improvement of Bacillus Calmette-Guerin Vaccination on Adult Atopic Asthma A Cohort Study

    

Postvaccination

  

Dependent Variables

Prevaccination

4 Wk

8 Wk

12 Wk

6 Mo

9 Mo

Thrice BCG Group

      

   PEFR (L/min)

360.5 ± 61.1

403.5 ± 71.9*,†

409.5 ± 63.9*,†

428.0 ± 77.6*,†

398.3 ± 101.0*,‡

380 ± 86.1§,‡

   FEV1 (L)

2.02 ± 7.6

  

2.33 ± 0.7*,†

  

   MMEV (L/s)

2.52 ± 1.3

  

3.12 ± 1.3*,†

  

   Eosinophil count (/μL)

608 ± 493.1

  

516 ± 522.1§,‡

453.9 ± 313.1§,‡

410 ± 299.0*,‡

   TSIgE (IU/mL)

1366 ± 1934.6

  

1395 ± 1563.7§,‡

1502.82 ± 2184.0§,‡

1440 ± 2084.4§,‡

   IFN-γ (pg/mL)

3.55 ± 2.2

  

4.22 ± 3.8§,‡

4.58 ± 2.8*,†

4.67 ± 0.5*,‡

   IL-4 (pg/mL)

0.04 ± 0.039

  

0.08 ± 0.05*,‡

0.09 ± 0.03*,†

0.1 ± 0.04*,†

   TGF-β1 (pg/mL)

54,396 ± 6908

  

50,720 ± 7111.4*,‡

38,066 ± 9279||,‡

48,271 ± 9634||,‡

Placebo Group

    

Single BCG Group

   PEFR (L/min)

360 ± 53.3

343 ± 67.4§,†

325 ± 63.8*,†

315.50 ± 72.9*,†

371 ± 73.98§,‡

346 ± 95.8§,‡

   FEV1 (L)

2.04 ± 0.65

  

1.64 ± 0.5*,†

  

   MMEV (L/s)

2.51 ± 1.2

  

2.01 ± 1.95*,†

  

   Eosinophil count (/μL)

649 ± 580.7

  

393 ± 358.4*,‡

569 ± 553.7§,‡

593 ± 582§,‡

   Total IgE (IU/mL)

887 ± 794.4

  

1053 ± 863.2§,‡

927 ± 1076.3§,‡

791 ± 1094.3§,‡

   IFN-γ (pg/mL)

3.65 ± 1.8

  

3.85 ± 1.95§,‡

5.25 ± 0.90*,†

4.81 ± 1.30*,‡

   IL-4 (pg/mL)

0.08 ± 0.13

  

0.08 ± 0.11§,‡

0.16 ± 0.09*,†

0.16 ± 0.13*,†

   TGF-β1 (pg/mL)

53,910 ± 7525

  

51,480 ± 6084.9§,‡

40,853 ± 12,772||,‡

45,942 ± 9453||,‡

  1. Values are expressed as mean or median ± SD; *P < 0.05; ||P < 0.001; §P > 0.05.
  2. Bold line separates the first and second phases; P < 0.05 between groups; P > 0.05 between groups.